Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Acorda Therapeutics
(NQ:
ACOR
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acorda Therapeutics
< Previous
1
2
3
4
5
6
7
8
Next >
Acorda Therapeutics Reports First Quarter 2023 Financial Results
May 11, 2023
From
Acorda Therapeutics
Via
Business Wire
3 Penny Stocks to Avoid as Interest Rates Rise in 2023
May 11, 2023
This article reveals the worst penny stocks to invest in for 2023, amid rising interest rates and a deteriorating macro environment.
Via
InvestorPlace
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
May 10, 2023
From
Acorda Therapeutics
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 09, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
May 09, 2023
We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday!
Via
InvestorPlace
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
May 09, 2023
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
12 Health Care Stocks Moving In Monday's Intraday Session
May 08, 2023
Via
Benzinga
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
May 08, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
May 04, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
April 24, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
April 03, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
March 27, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 09, 2023
From
Acorda Therapeutics
Via
Business Wire
ESTEVE Launches INBRIJA® in Spain
March 07, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
March 06, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
February 14, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics to Present at Sequire Biotechnology Conference
January 31, 2023
From
Acorda Therapeutics
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
January 23, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 05, 2023
Via
Benzinga
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
January 05, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
December 22, 2022
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
December 20, 2022
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
December 05, 2022
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
November 11, 2022
From
Acorda Therapeutics
Via
Business Wire
How Is The Market Feeling About Acorda Therapeutics?
November 09, 2022
Acorda Therapeutics's (NASDAQ:ACOR) short percent of float has risen 230.3% since its last report. The company recently reported that it has 792 thousand shares sold short, which is 3.27% of all...
Via
Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
November 08, 2022
Gainers
Via
Benzinga
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
November 04, 2022
From
Acorda Therapeutics
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 02, 2022
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million.
Via
Benzinga
Acorda Therapeutics Reports Third Quarter 2022 Financial Results
November 01, 2022
From
Acorda Therapeutics
Via
Business Wire
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
November 02, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.